Skip to main content
. 2015 Jun 10;9(9):1783–1798. doi: 10.1016/j.molonc.2015.06.001

Figure 1.

Figure 1

Dasatinib treatment changes conventional glioma cell line migration, growth, and morphology in culture. (A) Dasatinib treatment (10 μM) reduces migration of conventional glioma cell lines toward media containing the following concentrations of FBS: LN229 and SF767: 0.5% FBS; U251 and TP483: 2% FBS; U87: 5% FBS. Error bars are SEM, n = 4. *significantly different vs. vehicle (p < 0.01) (B) Dasatinib treatment (10 μM) reduces growth of LN229 and SF767 glioma cell lines in culture. LN229 cell number with dasatinib is significantly different from vehicle‐treated at days 3 and 4 in culture (p < 0.001). SF767 cell number with dasatinib is significantly different from vehicle‐treated at 2, 3, and 4 days in culture (p < 0.001). Error bars are SEM; the data is a combination of n = 5 independent experiments. (C) Dasatinib treatment (10 μM) changes the morphology of LN229 and SF767 cells by rearranging the actin cytoskeleton, reducing (LN229) or eliminating (SF767) actin stress fibers. LN229 and SF767 cells were plated on coverslips, treated with DMSO vehicle or 10 μM Dasatinib for 24 h, then fixed and stained with phalloidin to visualize the actin cytoskeleton and DAPI to visualize the nucleus. The 20 μm scale bar applies to all images.